Study S002301
A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With Metformin Alone
Registration
Registered primary outcomes
- Change in HbA1c (glycosylated hemoglobin) from baseline to study termination (Week 30) [Baseline (Day 1), Week 30]
Linked records (4)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0018919 | Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Pencek R, Postgraduate medicine | 2012 | Randomized trial | PMID 22913891DOI | cites ClinicalTrials.gov:NCT00039013; registry reference DERIVED:22913891 |
| R0026474 | Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Fineman MS, Diabetes, obesity & metabolism | 2012 | Other | PMID 22236356DOI | cites ClinicalTrials.gov:NCT00039013; registry reference DERIVED:22236356 |
| R0025778 | Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Ratner RE, Diabetes, obesity & metabolism | 2006 | Randomized trial | PMID 16776749DOI | registry reference RESULT:16776749 |
| R0022664 | Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. DeFronzo RA, Diabetes care | 2005 | Randomized trial | PMID 15855572DOI | registry reference RESULT:15855572 |